Tranzactioneaza Sellas Life Sciences Group Inc (US.SLS) - 9.07 USD (%) Tranzactioneaza
Indici
Descriere companie
SELLAS Life Sciences Group, Inc. (https://www.sellaslifesciences.com/) is a biopharmaceutical company that is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company’s product candidates include galinpepimut-S and nelipepimut-S. Its lead product candidate, galinpepimut-S is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a spectrum of hematologic cancers and solid tumor indications. Its nelipepimut-S is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.